Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders Equity

v3.21.1
Consolidated Statements of Changes in Stockholders Equity - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Beginning Balance, Shares at Dec. 31, 2018 9,442,537        
Beginning Balance, Amount at Dec. 31, 2018 $ 944 $ 23,962,920 $ (57,431) $ (13,967,030) $ 9,939,403
Shares issued on conversion of convertible debentures, shares 1,866,467        
Shares issued on conversion of convertible debentures $ 187 5,972,321 5,972,508
Common stock issued to settle deferred purchase consideration,shares 341,235        
Common stock issued to settle deferred purchase consideration $ 34 1,027,279 1,027,313
Common stock issued to settle liabilities, shares 284,721        
Common stock issued to settle liabilities $ 28 1,009,953 1,009,981
Bonus shares issued to convertible debenture holders, shares 14,082        
Bonus shares issued to convertible debenture holders $ 1 45,064 45,065
Stock based compensation expense   201,106     201,106
Promissory note, related party applied to warrant exercise        
Foreign currency translation adjustment     (119,286)   (119,286)
Net income (loss)       (9,274,805) (9,274,805)
Ending Balance, Shares at Dec. 31, 2019 11,949,042        
Ending Balance, Amount at Dec. 31, 2019 $ 1,194 32,218,643 (176,717) (23,241,835) 8,801,285
Shares issued on conversion of convertible debentures, shares 230,326        
Shares issued on conversion of convertible debentures $ 23 738,981     739,004
Common stock issued to settle deferred purchase consideration,shares 354,105        
Common stock issued to settle deferred purchase consideration $ 36 1,207,409     1,207,445
Common stock issued to settle liabilities, shares 8,469        
Common stock issued to settle liabilities $ 1 46,665     46,666
Bonus shares issued to convertible debenture holders        
Stock based compensation expense   518,506     518,506
Public offering proceeds, shares 4,166,666        
Public offering proceeds $ 417 10,005,832     10,006,249
Expenses related to public offering   1,040,127     (1,040,127)
Proceeds from warrants exercised, shares 3,278,004        
Proceeds from warrants exercised $ 328 8,541,568     8,541,896
Promissory note, related party applied to warrant exercise, shares 43,222        
Promissory note, related party applied to warrant exercise $ 4 108,052     108,056
Fair value of warrants issued on convertible debt extensions   719,390     719,390
Foreign currency translation adjustment     444,665   444,665
Net income (loss)       (9,936,682) (9,936,682)
Ending Balance, Shares at Dec. 31, 2020 20,029,834        
Ending Balance, Amount at Dec. 31, 2020 $ 2,003 $ 53,064,919 $ 267,948 $ (33,178,517) $ 20,156,353